|
Synonyms: AR-320 | MEDI4893
Compound class:
Antibody
Comment: Suvratoxumab is a clinical stage fully human IgG1 monoclonal antibody that prevents binding of Staphylococcus aureus alpha-toxin to its cellular receptor ADAM10 [2]. It is being developed for the prevention of nocosomial pneumonia caused by S. aureus.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 10441 | suvratoxumab |
| Synonyms |
| AR-320 | MEDI4893 |
| Database Links |
|
| Specialist databases | |
Antibiotic DB
|
Suvratoxumab, MEDI4893, LC-10 |
| IMGT/mAb-DB | 716 |
| Other databases | |
| CAS Registry No. | 1629620-18-3 (source: Scifinder) |
| ChEMBL Ligand | CHEMBL3989997 |
| DrugBank Ligand | DB15172 |
| GtoPdb PubChem SID | 496703331 |
| Search PubMed clinical trials | suvratoxumab |
| Search PubMed titles | suvratoxumab |
| Search PubMed titles/abstracts | suvratoxumab |
